Filing Flows › Fate Therapeutics (FATE) › Q4 2025
Fate Therapeutics (FATE) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Fate Therapeutics (FATE) reported revenue of $1.4M for the fourth quarter 2025 (Q4 2025), -26% from a year earlier and -21% from the quarter before.
Fate Therapeutics, Q4 2025: revenue $1.4M (-26% year over year), net loss $32.4M, operating cash flow −$23.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | -21% | -26% |
| Operating profit | −$34.7M | — | — |
| Net earnings | −$32.4M | — | — |
| Operating cash flow | −$23.3M | — | — |
What changed
Revenue was $1.4M in Q4 2025, down 26% year over year and down 21% from the previous quarter.
Operating costs exceeded revenue by $34.7M, an operating margin of -2536.2%. Total costs fell 43% while revenue fell 26%. The quarter ended with a net loss of $32.4M, wider than the previous quarter's $32.2M loss.
Operating cash flow was −$23.3M. Non-cash charges added back $3.1M of depreciation and amortization and $5.5M of share-based compensation. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$24.5M.
Questions
What was Fate Therapeutics' revenue in the fourth quarter 2025?
Fate Therapeutics (FATE) reported revenue of $1.4M for the fourth quarter 2025 (Q4 2025), -26% from a year earlier and -21% from the quarter before.
Source: Fate Therapeutics 10-K on SEC EDGAR.